News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


ONC201 Trial for Histone Mutant Glioma Begins at NYU


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 This mutation is a bad prognostic sign, but they have a 15 year survivor on this medication.  


Posted on: 11/05/2017

ONC201 Trial for Histone Mutant Glioma Begins at NYU

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740